About 11 results found for searched term "79-14-1" (0.051 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M2028 | Fludarabine | STAT |
| Fludara; NSC 118218; Fludarabinum; F-ara-A | ||
| Fludarabine (NSC 118218) is a STAT1 activation inhibitor and a DNA synthesis inhibitor. Fludarabine inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase. Fludarabine markedly inhibited VSMC proliferation in cell culture. Fludarabine also induces significant reduction of STAT-1 phosphorylation, whereas it does not change JAK2 activation. Fludarabine exhibits antiproliferative activity (IC50 = 1.54 μM in RPMI cells) and triggers apoptosis through increasing Bax and decreasing Bid, XIAP and survivin expression. | ||
| M6981 | ML 365 | Potassium Channel |
| ML 365 is a potent and selective K2P3.1 TASK-1 channel blocker. | ||
| M16568 | 3,4'-Dihydroxy-3',5,7-trimethoxyflavan | Flavonoids |
| 3,4'-Dihydroxy-3',5,7-trimethoxyflavan | ||
| M18810 | Rebaudioside E | Others |
| Rebaudioside E | ||
| M20951 | Glycolic acid | Others |
| dicarbonous acid, hydroxyacetic acid, hydroacetic acid | ||
| Glycolic acid (or hydroxyacetic acid) is the smallest alpha-hydroxy acid. Due to its excellent capability to penetrate skin, glycolic acid is often used in skin care products, most often as a chemical peel. | ||
| M24797 | Remtolumab | TNF Receptor |
| ABT-122 | ||
| Remtolumab (ABT-122) is a dual-variable domain immunoglobulin that neutralises both tumor necrosis factor α (TNFα) and IL-17A. Remtolumab shows dual inhibition of TNFα and IL-17A. Remtolumab can be used for rheumatoid arthritis (RA) research. | ||
| M24798 | Lutikizumab | IL Receptor/Related |
| ABT-981 | ||
| Lutikizumab (ABT-981) is an anti-IL-1α and IL-1β dual variable domain immunoglobulin. Lutikizumab binds and inhibits IL-1α and IL-1β. Lutikizumab can be used for the research of osteoarthritis. | ||
| M24799 | Elezanumab | TGF-beta/Smad |
| ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody | ||
| Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism. | ||
| M24800 | Dilpacimab | VEGFR/PDGFR |
| ABT165; PR1283233 | ||
| Dilpacimab (ABT165) is a potent dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways.. Dilpacimab can be used in research of cancer. | ||
| M29712 | TH1760 | Others |
| TH1760 is an inhibitor of NUDIX-type 15 (NUDT15) with an IC50 value of 25 nM. TH1760 sensitizes cells to 6-thioguanine by enhancing the accumulation of 6-thio- (d) GTP in nucleic acids. TH1760 enhances the anti-leukemia effect of thiopurine. | ||
| M55660 | MTX-531 | EGFR/HER2 |
| MTX531 | ||
| MTX-531 is a first-in-class, potent and selective inhibitor of EGFR and PI3K, with IC50s of 14.7 nM and 1.1-233 nM (differ in subtype). MTX-531 can also act as a weak agonist of PPARγ, with the EC50 of 3.4 μM in 293H cells. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
